All these mechanisms among others are still under active investigation, but what is clear is that the great benefit of SGLT2 inhibitors in heart disease contributes to their favorable effects on the kidneys by slowing down the vicious cardiorenal circle in diabetes (37) (Figure 1). The gene discussed is SLC5A2; the disease is diabetes mellitus.